ArticleJournal of thoracic disease2025
Enhanced protein carbonylation is associated with prolonged fibrin clot lysis in patients with advanced lung cancer: impact on long-term mortality.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differential Oxidative Stress Profiles in Circulating and Peritumoral Adipose Tissue Across Stages of Colorectal Cancer.International journal of molecular sciences · 2026Article
- Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increased oxidative stress (OS) and impaired fibrinolysis contribute to carcinogenesis and have been observed in lung cancer (LC) patients. The relationship between protein carbonylation (PC) and fibrinolysis in LC is unclear. We aimed to evaluate whether PC levels contribute to the prothrombotic properties of fibrin clots, including impaired fibrinolysis, and whether PC may impact mortality in patients with LC. Methods: In this cohort study, we assessed 147 patients aged 64.2±7.0 years (men, n=45, 30.6%) with inoperable LC (stage IV, n=90, 61.2%). PC content was determined using the assay by Becatti Results: Baseline PC levels [median 3.01 (interquartile range, 2.53-3.87) nmol/mg protein] were elevated in 145 patients (99%). Stage IV patients exhibited 14.4% higher PC levels than those in stage III (P=0.009), with no association with demographics, comorbidities, or metastatic disease. PC levels were positively associated with CLT (r=0.35, P<0.001), but not with other fibrin-related variables. Proportional hazard Cox regression analysis showed that higher PC values (>3.87 nmol/mg protein), adjusted for age, statin use, active smoking, and stage IV status, were associated with increased mortality compared to lower PC values (hazard ratio =1.71, 95% confidence interval: 1.13-2.61, P=0.01). Conclusions: Increased PC, associated with cancer stage and prolonged fibrin CLT, may increase the risk of death in inoperable LC patients, which suggests an involvement of OS in LC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.